


01 - 29 - 07

186



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No.: 03-075-US)

In the Application of:

Saus, et al.

Serial No. 10/772,656

Filed: February 5, 2004

Title: Novel Goodpasture Antigen-
Binding Protein Isoforms and
Protein Misfolded-Meditaed
Disorders

Group Art Unit: 1642

Examiner: Mark Halvorson

Confirmation No.: 6152

Mail Stop: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Dear Sir:

In regard to the above-identified U.S. patent application;

1. We are transmitting herewith the attached:


- ☒ Transmittal Letter (in duplicate);
- ☒ Compliance with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- ☒ Response to Notice to Comply Mailed January 16, 2007;
- ☒ Sequence Listing (144 sheets and Computer Readable CD);
- ☒ Notice to Comply; and
- ☒ Return Receipt Postcard

2. With respect to fees:

- ☒ No fee is believed to be due.
- ☒ Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.

3. CERTIFICATE OF MAILING BY "EXPRESS MAIL" UNDER 37 CFR § 1.10: The undersigned hereby certifies that this Transmittal Letter and the papers, as described hereinabove, are being deposited with the United States Postal Service with sufficient postage as "Express Mail Post Office to Addressee" in a box addressed to: PO Box 1450, Alexandria, VA 22313-1450, on this 25th day of January, 2007. Express Mail No. **EV839403254US**.

Respectfully submitted,



David S. Harper

Registration No. 42,636



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 03-075-US)

In application of)	
Saus, et al.)	Examiner: Mark Halvorson
)	
Serial No.: 10/772,656)	
)	Group Art Unit: 1642
Filed: February 5, 2004)	
)	
For: Novel Goodpasture Antigen-)	Confirmation No.: 6152
Binding Protein Isoforms and)	
Protein Misfolded-Meditaed Disorders)	

Mail Stop **Amendement**
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-14501

RESPONSE TO NOTICE TO COMPLY MAILED JANUARY 16, 2007

Dear Sir:

Please amend the above reference case by entering the substitute Sequence Listing. The Sequence Listing has been updated to correct an error detected by the Patent Office. The Sequence Listing has been generated from the specification, figures, and claims and does not constitute new matter.

Respectfully submitted,

Date:

1-26-07


David S. Harper, Ph.D.
Registration No. 42,636

Telephone: 312-913-0001
Facsimile: 312-913-0002

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive
Chicago, IL 60606



UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/772,656	02/05/2004	Juan Saus	03-075-US	6152

20306 7590 01/16/2007
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP
300 S. WACKER DRIVE
32ND FLOOR
CHICAGO, IL 60606

EXAMINER	
HALVORSON, MARK	
ART UNIT	PAPER NUMBER
1642	


SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
30 DAYS	01/16/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

DOCKETED

JAN 22 2007
Seq. 1stg Docs. 2-15-07
DUE DATE: _____
BY: E. J. On



Notice to Comply	Application No. 10/772,656	Applicant(s) Saus et al	
	Examiner Mark Halvorson	Art Unit 1642	

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: New CRF and paper Sequence Listing including SEQ ID NO:104 has not been filed.

Applicant Must Provide:

- ☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.**
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 or (703) 308-2923

For CRF Submission Help, call (703) 308-4212 or 308-2923

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

Misook Yu
MISOOK YU
PRIMARY EXAMINER

Misook Yu
MISOOK YU
PRIMARY EXAMINER